Interagency Collaboration for Patient-Centered Antibacterial Drug Development.
Aug 6, 2025DOI: 10.1093/cid/ciaf298Journal ArticleCID
Written by: Jessica Howard-AndersonSarah B DoernbergDennis DixonRamya GopinathDaniel RubinTori KinamonPeter KimDeborah CollyarSara E CosgroveVance G FowlerHenry F ChambersScott R EvansThomas L HollandHeather A KingHelen W Boucher
Find these authors on Roon
VF
Dr. Vance Fowler
General ID · Duke University
HB
Dr. Helen Boucher
Transplant/Immunocompromised States · Tufts
Summary
This manuscript presents key advances of the Antibacterial Resistance Leadership Group (ARLG) Innovations Task Force, a collaboration focused on improving endpoints for registrational trials of antibacterial drugs, including health-related quality-of-life measures, for common acute infections. This group includes members from the United States Food and Drug Administration, National Institutes of Health, academia, industry, and patient representatives to amplify patient voices and ensure that the endpoints are meaningful to how patients feel, function, and survive.